Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.

NCT Number	NCT06652087
Lead Sponsor	I.M. Sechenov First Moscow State Medical University
Conditions	Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction
Enrollment	40 participants
Start Date	2024-09-02
Primary Completion	2026-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2024-10-22